Latest Safety News

Eclipse Metals Ltd reported significant progress in its March 2025 quarter, highlighting new high-grade rare earth mineralisation in Greenland and a strategic uranium project earn-in agreement in Australia.

Noble Helium has postponed its Western margin drilling program and appointed Dennis Donald as Non-Executive Chairman, while actively pursuing refinancing and cost-saving measures to sustain its flagship North Rukwa Project.

Vectus Biosystems advances its lead fibrosis drug VB0004 with validated Phase I safety data and strategic cost reductions, while actively pursuing licensing partnerships in China.

Renascor Resources reports significant engineering advances that increase high-value graphite production by 60%, reduce operating costs, and confirm a safer, eco-friendly purification process.

Kinetiko Energy reports encouraging progress in South African gas exploration, with improved well performance and a drilling optimisation study revealing key production enhancements.

Dimerix Limited advances its Phase 3 kidney disease trial with FDA acceptance of proteinuria as a primary endpoint and clinches a lucrative licensing agreement in Japan worth up to AU$107 million plus royalties.

Geopacific Resources has completed a $40 million entitlement offer to fund a major drilling campaign and an updated Definitive Feasibility Study for its 1.67 million ounce Woodlark Gold Project, positioning the company for significant resource growth and project advancement.

Saferoads Holdings reports a modest quarterly profit driven by cost cuts and prepares to settle the sale of its Road Safety Rentals business, aiming to clear debt and refocus on product sales growth.

dorsaVi’s Q3 FY25 report reveals growing adoption of its AI-powered video movement analysis in the US, a new elite athlete research partnership, and the launch of a pioneering 3D ACL injury prevention test.

Norwest Minerals Limited has launched a $4.85 million entitlement offer to fund an aggressive drilling campaign and mining option review at its Bulgera Gold project, aiming to significantly expand its gold resource amid soaring gold prices.

Argent BioPharma reports significant operational savings through manufacturing outsourcing, encouraging Phase IIb results for CimetrA®, and key regulatory approvals for cannabinoid therapies in Germany.

Pointerra Limited’s Q3 FY25 results reveal delayed invoicing milestones pushed into Q4, yet strong progress across multiple sectors and promising product development underpin an optimistic cashflow outlook.